Edralbrutinib clinical trials
Also written SHR1459.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses edralbrutinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
11 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2018 | 3 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Jiangsu HengRui Medicine Co., Ltd. (9) · Reistone Biopharma Company Limited (1) · TG Therapeutics, Inc. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses edralbrutinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell MalignanciesTerminatedPhase 1TG Therapeutics, Inc.NCT03671590Written as TG-1701How we know
- Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous NephropathyActive, not recruitingPhase 2Reistone Biopharma Company LimitedNCT05136456Written as SHR1459 Low DoseHow we know
- A Trial of DDI Between SHR1459 and Efavirenz With Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05560360Written as SHR1459 tabletHow we know
- Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell NeoplasmstumorStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT03664297Written as SHR1459How we know
- A Bioavailability Study of SHR1459 on Healthy Chinese VolunteersCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04395053Written as SHR1459How we know
- Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male VolunteersStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05095337Written as [14C]SHR1459How we know
- A Phase I Study of SHR1459 in Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04455100Written as SHR1459/ItraconazoleHow we know
- SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's LymphomaStatus unknownPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT04948788Written as SHR1459 ;YY-20394How we know
- Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)CompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04649723Written as SHR1459How we know
- A Food Effect Study of SHR1459 on Healthy Chinese Adult SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04291846Written as SHR1459 fasted in P1, high-fat diet in P2How we know
- Safety, Tolerability and PK/PD of SHR1459 in Healthy VolunteersStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT03668509Written as SHR1459How we know
Codes
What other systems call edralbrutinib · ClinicalTrials.gg INT017909
- UNII (FDA) SG5I5QTR4EEDRALBRUTINIBOne source FDA
- NCI Thesaurus C175775EdralbrutinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | SG5I5QTR4E | EDRALBRUTINIB | One source FDA |
| NCI Thesaurus | C175775 | Edralbrutinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.